[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学会重型肝炎与人工肝学组.肝衰竭诊治指南(2012年版).中华肝脏病杂志, 2013,21:177-183 .
[2] Moreau R, Jalan R, Gines P, Pavesi Met,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.Gastroenterology, 2013,144:1426-1437.
[3] Kakisaka K, Kataoka K, Onodera M, et al.Alpha-fetoprotein: a biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure.Hepatol Res,2015,45:E12-20.
[4] Reyes-Soffer G, Moon B, Hernandez-Ono A, et al.Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.Sci Transl Med,2016,8(323):323ra12
[5] Chen E Q , Bai L , Gong D Y , et al. Employment of digital gene expression profiling to identify potential pathogenic and therapeutic targets of fulminant hepatic failure. J Transl Med, 2015, 13:22
[6] Chen E Q , Wang M L , Zhang D M , et al. Plasma apolipoprotein A-V predicts long-term survival in chronic hepatitis B patients with acute-on-chronic liver failure. Sci Rep, 2017, 7:45576.
[7] Macdonald S , Andreola F , Bachtiger P , et al. Cell death markers in patients with cirrhosis and acute decompensation. Hepatology, 2018, 67:989-1002.
[8] Matsue Y , Tsutsumi M , Hayashi N , et al. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. Plos One, 2015, 10:e0118744.
[9] Fan X, He C, Jing W, et al. Intracellular Osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res, 2015, 75:86-97.
[10] Patouraux S , Rousseau D , Rubio A , et al. Osteopontin deficiency aggravates hepatic injury induced by ischemia-reperfusion in mice. Cell Death Dis, 2014, 5:e1208.
[11] Liu Y , Cao B L , Chen C R , et al. Osteopontin promotes hepatic progenitor cell expansion and tumorigenicity via activation of β-Catenin in mice. Stem Cells, 2015, 33:3569-3580.
[12] Lee S H , Park J W , Woo S H , et al. Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice. Oncotarget, 2016, 7:87219-87231.
[13] Liu L, Lu J, Ye C, et al. Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure. Biomed Rep, 2018,8:166-172.
[14] Ming-Jiang Xu, Feng D , Wu H , et al. Liver is the major source of elevated serum lipocalin‐2 levels after bacterial infection or partial hepatectomy: A critical role for IL‐6/STAT3. Hepatology, 2015, 61:692-702.
[15] Ariza X , Graupera I , Coll M , et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol,2016,65:57-65.
[16] Wang K, Wu ZB, Ye YN, et al.Plasma interleukin-10: a likely predictive marker for hepatitis B virus-related acute-on-chronic liver failure. Hepat Mon, 2014, 14:e19370.
[17] Shi Y, Wu W, Yang Y, et al.Decreased Tim-3 expression is associated with functional abnormalities of monocytes in decompensated cirrhosis without overt bacterial infection. J Hepatol, 2015, 63:60-67.
[18] Du X , Shi Y , Yang Y , et al. DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure. Liver Int, 2018,38:229-238.
[19] Chen E Q , Bai L , Gong D Y , et al. Employment of digital gene expression profiling to identify potential pathogenic and therapeutic targets of fulminant hepatic failure. J of Transl Med, 2015, 13:22.
[20] Zhang G L , Xie D Y , Lin B L , et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure. J Gastroenterol and Hepatol, 2013, 28:513-521.
[21] Niu, Ying-Hua. Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure. World J Gastroenterol, 2013, 19:4146-4154.
[22] Li C , Wang Y , Wang S , et al. Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. Jof Virol, 2012, 87:2193-2205.
[23] Chen W , Yan Z H , Wang Y M , et al. Genome-wide microarray-based analysis of miRNAs expression in patients with acute-on-chronic liver failure. Hepatobiliary Pancreatic Dis Int, 2014, 13:32-39.
[24] Yu D S , An F M , Gong B D, et al.The regulatory role of microRNA-1187 in TNF-α-mediated hepatocyte apoptosis in acute liver failure. Int J Mol Med, 2012, 29:663-668.
[25] Biggins S W , Kim W R , Terrault N A, et al.Evidence-based incorporation of serum sodium concentration into MELD.Gastroenterology, 2006, 130:1652-1660.
[26] Jalan R,Saliba F,Pavesi M,et al.Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol, 2014,61:1038-1047.
[27] Johnson PJ, Berhane S, Kagebayashi C,et al.Assessment of Liver Function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI Grade. J Clin Oncol, 2015, 33:550-558.
[28] Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine, 2017, 96:e7142.
[29] Gao F, Sun L,Ye X,et al.Development and validation of a prognostic model for acute-on-chronic hepatitis B liver failure. Eur J Gastroenterol Hepatol, 2017, 29:669-678.
[30] Wu T, Li J, Shao L,et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.Gut,2018,67:2181-2191. |
